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Background/aim: To assess the immune status against tetanus in relation to self-declared vaccination status among an adult population
in Yozgat, Turkey.
Methods: Questionnaires and blood specimens were collected from 267 individuals over 18 years of age in Yozgat, Turkey. Antitetanus
antibodies were determined quantitatively by enzyme-linked immunosorbent assay.
Results: Among the 267 subjects (mean age 43.4 ± 15.6; male:female, 133:134) 168 (62.9%) had protective level of tetanus antibody titers.
There was a characteristic distribution of the tetanus antibody titers in different age groups as it dropped with increasing age. Protective
immunity was obtained in 74.1% of urban and 47.9% of rural participants. The lowest immunity was observed among farmers (53.3%)
and housewives (55.6%) when compared to other occupations. Protective antibody titers were detected in 25% of the individuals who
had not finished any school, while the rate was 83.7% in those who had graduated from university. While the protection rate in women
who had been vaccinated during pregnancy was 78.3%, this rate was 39.2% in nonvaccinated women.
Conclusion: Our findings confirm that only 62.9% of the population is immunized against tetanus, with a lack of coverage in particular
for the elderly and in rural areas. It is necessary to follow the recommendations for 10-year boosters for tetanus.
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1. Introduction
Tetanus develops through a neurotoxin called
tetanospasmin, which is secreted by Clostridium tetani
after entering the body through injuries. It is characterized
by painful and tonic muscle spasms that progress to
become quite heavy, and a high death rate (1). Clostridium
tetani, an obligate anaerobe, is a gram-positive bacillus
with motile and terminal spores. Bacteria, especially in
the oxygenic area, halt reproduction and form a resistant
spores shape from a vegetative shape. Spores can be found
in human, and especially animal, excrement, in sites
polluted with feces, in dung-heaps, and in dust and soil.
For this reason, it is not possible to completely eradicate
tetanus (2). Tetanus can be controlled by vaccination, and
is often seen in newborns, children, and young adults
in developing countries (1). More rarely, the disease can
appear in developed countries and in people over the age
of 50 as a result of incomplete vaccination and an irregular
descending vaccinated calendar based on reduced antitoxin
* Correspondence: dr_cigdemtr@yahoo.com
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levels over time (1). With adequate immunization, a serum
antitoxin level of 0.1 IU/mL and higher provides protection
against the disease. When tetanus toxoid is given 3 times at
1-month intervals for active immunization, at least 5 years
of protection is provided (3).
The aim of the present study was to determine the
seroprevalence of tetanus antitoxin levels among adults
in Yozgat and its relation to vaccination history, age, and
residence.
2. Materials and methods
2.1. Selected population, sample size and study design
This cross-sectional epidemiologic study was planned to
determine the tetanus antibody levels among adults in
Yozgat. With a sample of approximately 328,794 individuals
of 18 years of age or older in Yozgat, on the assumption that
65% of the individuals in this age group will have protective
levels of antitoxin, the required sample size was calculated
as 349 at a confidence interval of 95% and with a deviation
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2.2. Enzyme-linked assay
Antitetanus antibodies were determined quantitatively
by immunosorbent enzyme-linked assay (ELISA)
(Euroimmun, Lübeck-Germany) method in serum
samples. A 100-μL serum sample from each patient was put
in each well in the test strip. The intention in this regard was
to form the immunocomplex by combining the antibodies
found in the human serum with the antigens coated on the
test strips. After the removal of uncoated immunoglobulin
through washing, enzyme conjugates were added. When
the substrate solution was added, a blue color appeared
as a result of substrate use by the enzyme, after which the
color was observed to change from blue to yellow with the
addition of a stop solution. Optical density values were
obtained by reading the color in a spectrophotometer, and
a standard curve was obtained from the optical density
values marked on paper. Immunoglobulin G (IgG) levels,
corresponding to the absorbance values of the serum
samples, were determined in IU/mL. When the test results
were interpreted according to the current literature, the
respondents with a tetanus IgG level of <0.1 IU/mL were
determined to be inadequately immune or sensitive,
and those with a tetanus IgG level of ≥0.1 IU/mL were
evaluated as definitively immune.
2.3 Statistical analysis
For the statistical analysis, a Student’s t test for independent
and paired continuous variables and proportional
comparisons of categorical variables were performed
using chi-square tests, while a Fisher’s exact test was used
when data were sparse. The results are expressed as mean
± standard deviation (SD), unless indicated otherwise.
Spearman’s test was used for the correlation analyses. A P
value of <0.05 was considered to be statistically significant.
Statistics were run using the STATA 11.0 Software Package
(College Station, TX, USA).

3. Results
Among the 267 subjects (mean age, 43.4 ± 15.6 years old;
male:female, 133:134) 168 (62.9%) had tetanus antibody
titers above 0.1 IU/mL. Statistically significant differences
in antibody levels were observed between the males and
females, with the male participants observing higher
protective tetanus antitoxin levels (P = 0.035). There was
a characteristic distribution of the tetanus antibody titers
among different age groups, which dropped with increasing
age. Spearman’s correlation analysis showed a significant
negative correlation between age and antibody titers (r =
−0.5231, P <0.001) (Figure). Seropositivity against tetanus
in the different age groups is shown in Table 1. Only 1
subject declared that he had not been vaccinated against
tetanus and had no immunity. Protective immunity was
obtained in 74.1% of urban and 47.9% of rural participants
(P = 0.001). The lowest immunity was observed among
farmers (53.3%) and housewives (55.6%) when compared
to other occupations. Protective antibody titers were
detected in 25% of the individuals who had not finished
5
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of 5%. According to this, 267 of those who applied were
included in the study, and the distribution of sex and age
was taken into account. Data and serum collection was
conducted between June 2012 and September 2012. After
filling in the informed consent form, the respondents were
subjected to face-to-face interviews using a questionnaire.
A standard form was filled in, including the subject’s
age, sex, education level, presence of childhood vaccines,
marital status, pregnancy, military service status, current
chronic diseases, drug and alcohol use, accident or injury
history, and previous tetanus vaccination status. Each
participant provided a 10-cc blood sample to determine
their tetanus antibody levels, and the serum was separated
through centrifugation and kept at −80 °C until the day
of study. The study was approved by the Bozok University
clinical research ethics committee (Registration number:
03.01.2012/03).
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Figure. Tetanus antibody levels and age correlation graph (r =
−0.5231, P <0.001).
Table. 1. Seropositivity against tetanus in the different age groups.
Age groups (years)

Seropositivity n (%)

18–20

14 (78%)

21–30

40 (97.6%)

31–40

54 (78.3%)

41–50

39 (69.6%)

51–60

13 (31.7%)

61–70

5 (17.9%)

71–80

3 (21.4%)
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any school, while the rate was 83.7% in individuals who
had graduated from university (P = 0.001). Spearman’s
correlation analysis showed a significant positive
correlation between education level and antibody titers
(r = 0.346, P <0.001). Furthermore, 60 of the 134 women
stated that they had been vaccinated for tetanus during
pregnancy, and 47 (78.3%) of them were found to be
immune. Of the 134 women, 74 said that they had not been
vaccinated for tetanus during pregnancy, and 29 (39.2%) of
them were found to be immune (P <0.001). In this study, a
statistically significant relationship was identified between
tetanus immunity and the male sex, education, residence,
occupation, comorbidity, vaccination during pregnancy,
injury history, and vaccination during military service. In
contrast, no significant difference was identified in the rate
of immunity between subjects in terms of alcohol use or
place of birth. A univariate analysis of variables for tetanus
immunity is shown in Table 2.

4. Discussion
Tetanus is a vaccine-preventable disease that has a high
mortality rate, especially in people who are unvaccinated
or who have an incomplete vaccination program. The
age groups affected by tetanus vary according to the
development level of the country. Tetanus especially
occurs in elderly people in developed countries as a
result of antibody titers falling below the protective level,
while neonatal tetanus is mostly seen in undeveloped
or developing countries (4). In Turkey, tetanus toxoid
(TT) vaccinations began in 1935 and, since 1957, it has
been used in conjunction with the diphtheria-pertussistetanus (DPT) vaccine. TT vaccinations were scheduled
across Turkey by the Ministry of Health in 1985, and
since then tetanus vaccinations have been given as part
of a childhood vaccination program. Vaccinations are
given to children in the second, fourth, and sixth months
after birth, and at 12 months after the last vaccination.

Table 2. Univariate analysis of variables for tetanus immunity.
Characteristic

Immune cases
(n = 168)

Nonimmune cases
(n = 99)

P value

Age, years

37.1 ± 12.7

54.1 ± 14.3

<0.001

Sex, male

92 (54.8%)

41 (41.4%)

0.035

34 (20.2%)
134 (79.8%)

37 (37.4%)
62 (62.6%)

0.002

7 (4.2%)
38 (22.6%)
30 (17.9%)
52 (31%)
41 (24.4%)

21 (21.2%)
43 (43.4%)
13 (13.1%)
14 (14.1%)
8 (8.1%)

<0.001

Farmer
Employer
Worker
Housewife
Student
Self-employed

20 (11.9%)
30 (17.9%)
30 (17.9%)
48 (28.6%)
17 (10.1%)
23 (13.7%)

16 (16.2%)
9 (9.1%)
13 (13.1%)
42 (42.4%)
1 (1%)
18 (18.2)

0.004

Comorbidity (if any)
Diabetes mellitus
Chronic renal failure
Chronic liver disease
Malignancy

35 (20.8%)
18 (10.7%)
3 (1.8%)
11 (6.6%)
3 (1.8%)

39 (39.4%)
15 (15.2%)
6 (6.1%)
7 (7.1%)
11 (11.1%)

0.001
0.105
0.026
0.496
<0.001

Military service (for males only)

79 (85.9%)

40 (97.6%)

0.042

History of injury

71 (42.3%)

27 (27.3%)

0.014

History of vaccination during pregnancy

47 (61.8%)

13 (22.4%)

<0.001

Residence
Rural
Urban
Education
No school
Primary school
Secondary school
High school
University
Occupation
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A further dose is given at the age of 6, when the child
has reached school age. This application is referred to as
primary immunization, and a booster at the age of 10 is
recommended, plus tetanus vaccine is administered after
20 weeks of pregnancy in Turkey (http://www.shsm.gov.
tr/public/documents/legislation/bhkp/asi/neotetanoz/
MaternalveNeonetalTetanozEliminasyonSahaRehberi.
pdf). Furthermore, young men of military age are also
vaccinated against tetanus through routine vaccinations
during military service (5).
This study made an analysis of 267 people above 18
years of age living in Yozgat, among which the protection
from tetanus rate was found to be 62.9%. Protective levels
of tetanus antibody were found to be 68% to 86.4% in
different studies from Turkey (5–7). Different levels of
tetanus immunity have also been identified in different
countries. The rate of protection in a sample aged 0–95
years of age was found to be 70.7% in a study in Italy (8),
along with rates of 82.5% in Canada, 72% in Germany,
76.2% in India, 61.2% in Peru, and 47% in Kenya (9–13).
In terms of the age distribution in our study, tetanus
immunity below the age of 40 ranges from 77.8% to 97.6%
and it is noted that protection levels decrease gradually
with age. Furthermore, the immunity rate against tetanus
is 69.9% in the 41–50 age group and 31.7% in the 51–60 age
group. After this, the protection rate drops dramatically to
17.9% in the 61–70 age group, and 21.4% in those over
70 years of age. This can be explained by the fact vaccines
are administered during pregnancy, school, and military
service in those under 50 years of age.
In our study tetanus antitoxin levels significantly
decrease after 50 years of age, which is accepted as the limit
age. This can be explained by the fact that adult vaccination
is not a very common practice in Turkey. Therefore, older
people are expected to have a lower tetanus antitoxin
level. Tosun et al. in Manisa showed that antitoxin levels
significantly decrease with age in both women and men
especially after 50 years of age, which is accepted as the
limit age at which the antibody is likely to be negative (14).
In another study from Turkey a rate of protection of 56%
in respondents aged 50 years and above was reported (5).
In a further study from Turkey a rate of protection was
found of 58.3% between the ages of 40 and 50, 41.7%
between 50 and 60, 36.4% between 60 and 70 age, and
20% in those aged above 70 (7). Recent studies in different
countries show clearly that the elderly population is not
generally immune to tetanus, and tetanus seropositivity
was found to be 54% and 29% in people of a mean age
of 69 and 82, respectively, in the United States (15). The
seropositivity rate in Italy was found to be 43.4%, 26.6%,
27.9% and 17.1% in the 45–65, 65–74, 75–84, and ≥85 age

groups, respectively (8). Tetanus seropositivity was found
to be 83.6% in Finland, 57.1% in New Zealand, and 63.2%
in Israel in people aged over 50 years (16–18).
In our study, a higher level of tetanus IgG positivity was
found in males, and similarly high levels were reported in
males in studies from Germany and Greece also (10,19).
This high rate in the studies may be attributed to fact that
men are have more accidents.
We found a conflicting result in this study where
immunity was higher in individuals who had not carried
out military service than in those who had. Probably, the
high immunization rate that was found in individuals
who had not done military service is associated with a
younger age. The mean age of the individuals who had not
completed military service was 26.6 ± 13.7 and of those
who had was 46.4 ± 14.4 in this study.
In our study, in contrast to other studies in Turkey
(6,7), the immunization rate was significantly lower in
people living in rural areas when compared to those
living in city centers. We think that this may be attributed
to the lack of easy access to health care in rural areas. It
is possible that the rate of booster vaccination is lower
because, over time, physicians and individuals lose interest
in maintaining vaccine coverage in rural areas of Turkey
(20). In this study it was observed that immunity to tetanus
increased with education level, which was compatible
with another study from Turkey (21). According to the
information received from the participants, significantly
lower tetanus antibody levels were detected in those who
had not received routine vaccinations in the childhood
period. In our study, tetanus immunity was significantly
lower in people with a history of chronic disease. It can be
concluded that advancing age and having chronic diseases
are associated with reduced immunity to tetanus. In a
study that evaluated tetanus immunity in type-2 diabetes
mellitus patients, protection from tetanus was significantly
decreased in diabetic men (22). Tetanus vaccinations
administered during pregnancy directly affect the level of
antibodies in the elderly. With the advent of the maternal
and neonatal tetanus elimination program in 1995 in
Turkey, 2 doses of the tetanus vaccine were administered
(1 month apart), followed 6 months later by a third
dose, then 2 doses 1 year apart (http://www.shsm.gov.
tr/public/documents/legislation/bhkp/asi/neotetanoz/
MaternalveNeonetalTetanozEliminasyonSahaRehberi.
pdf). Protection was significantly higher in women who
were given the tetanus vaccine during pregnancy in this
study.
In conclusion, in this study, which was performed
with people of different sociocultural levels in Yozgat, we
identified a tetanus antitoxin protection level of 62.9%,
and it was determined that protection decreases with age.
The completion of the primary vaccinations administered
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during childhood, the vaccination of women during
pregnancy, and vaccinations after an accident or injury
protects adults against tetanus up to a certain period. The
importance of immunization efforts in both childhood
and pregnancy is increasing day by day, and campaigns
have been launched to work towards the prevention of
neonatal and maternal tetanus nationwide. However,
tetanus immunity decreases with age, and the high level of

tetanus mortality is an important issue to be kept in mind.
This study has shown the necessity of additional doses
over the age of 50, when tetanus protection is significantly
reduced.
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